TCGA-CX-7085-01A-21R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- MYOGENESIS+0.530
- ALLOGRAFT_REJECTION+0.520
- TNFA_SIGNALING_VIA_NFKB+0.510
- COMPLEMENT+0.480
- KRAS_SIGNALING_UP+0.470
- UV_RESPONSE_DN+0.460
- IL2_STAT5_SIGNALING+0.450
Top 10 suppressed
- E2F_TARGETS-0.670
- MYC_TARGETS_V2-0.670
- MYC_TARGETS_V1-0.660
- OXIDATIVE_PHOSPHORYLATION-0.610
- DNA_REPAIR-0.550
- G2M_CHECKPOINT-0.530
- MTORC1_SIGNALING-0.330
- GLYCOLYSIS-0.270
- PEROXISOME-0.220
- FATTY_ACID_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 67ed15bc-bbe5-4da7-81f9-002c54483f67 | — | — | 0.950 |
| 2 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.949 |
| 3 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.948 |
| 4 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.947 |
| 5 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.944 |
| 6 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.944 |
| 7 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.943 |
| 8 | MDT-AP-3277 | Med | Medulloblastoma | 0.942 |
| 9 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.938 |
| 10 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.938 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| MYOGENESIS | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.470 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.450 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |